In the news

Dr. Brian Dunkin, chief medical officer, Endoscopy, and Mike Jones, SVP and president, Endoscopy, discuss how endoluminal surgery (ELS) products from the recent Apollo Endosurgery acquisition represent a step forward in gastrointestinal (GI) care.

If you’re looking to advance your career, Mary Beth Moynihan, senior vice president of market access and chief marketing officer, has three words for you: “You’re worth it.”

Boston Scientific’s market capitalization has grown nearly 10 times larger since Mike Mahoney joined as CEO in 2011. He shared key insights about corporate strategy at DeviceTalks Boston in May.

Eric Thépaut, executive vice president and president, Europe, Middle East and Africa, shares how digital education platforms, real-time and on-demand technologies and remote case support are being utilized to help patients.

Data supporting use of key Boston Scientific electrophysiology and cardiac rhythm management therapies, and the WATCHMAN FLX™ Left Atrial Appendage Closure Device were presented at Heart Rhythm 2023, the annual meeting of the Heart Rhythm Society.

Camille Chang Gilmore, vice president, human resources, and global chief diversity, equity & inclusion officer, shares what she believes are the core elements in a successful DEI initiative and why creating a workplace that encourages empathetic, collaborative engagement is critical for the innovation that powers the medical device industry.

Boston Scientific’s new global chief medical officer is already well-known in cardiovascular device space circles. Dr. Ken Stein joined Boston Scientific in 2009 as SVP and chief medical officer of its Rhythm Management business. He became chief medical officer for the entire company on Feb. 13.

Clinical trials are an early step in device and therapy development which have significant impact on the types of products available to patients. Boston Scientific leaders share how the company is working to advance diversity in medical research.

Trevor Boylston had transitioned from female to male a decade before he started working at Boston Scientific. He shares reflections on how navigating the world of work can be enormously challenging for members of the transgender community and how he got involved in the company’s LGBTQ resource group.

Boston Scientific introduced the first U.S. Food and Drug Administration (FDA)-cleared single-use duodenoscope in 2019. Therefore, it is fitting that our first conversation in the Industry Perspective section of iGIE is with Michael Jones, senior vice president and president, Endoscopy for Boston Scientific.

Jenny Dandin is an R&D engineer at Boston Scientific. In a recent telephone interview with Career Communications Group, she shared a unique perspective from her experience as a female making her way as an engineer at a top medical device company.

Paudie O’Connor, senior vice president of supply chain, shares lessons learned from the last few years of macro supply chain challenges, and why Boston Scientific puts its people at the center.

Medical technology company Boston Scientific is among the organizations working to reverse the under-representation of women and people of color specifically Black patients, in clinical trials. Its aptly named Close the Gap program aims to level the medical playing field.

Boston Scientific Corp. scaled back some shifts at its facilities in Puerto Rico in light of travel advisories, a spokeswoman said. But its sites remain fully functional and the company expects operations to resume at normal levels once the storm subsides and travel advisories are lifted.

Brad Sorenson, executive vice president, Global Operations, and Paudie O’Connor, senior vice president of supply chain, discuss how supply chain has evolved in recent years, including strategic supplier relationships, resilience and continuity planning and sustainability.

Boston Scientific has been named one of Fast Company's Best Workplaces for Innovators for the third consecutive year—this year earning a callout as a best workplace for women.

Gail Beauregard, vice president of global total rewards at Boston Scientific, discusses how the company strives to create an organization where employees feel that they belong and can do their best work.

Camille Chang Gilmore, vice president, human resources and global chief diversity, equity and inclusion officer at Boston Scientific shares how the company’s diversity and inclusion efforts are promoting equity with its caring culture.

How has Boston Scientific evolved over the last decade? What is the difference between a leader and a manager? What does it mean to prioritize innovation? Charmain and CEO Mike Mahoney answers these questions and more during a sit down with DeviceTalks.

Boston Scientific’s WATCHMAN FLX™ is associated with fewer major adverse events and higher rates of success than its predecessor, according to an analysis of registry data by researchers at Yale School of Medicine. The study looked at 27,000 recipients of Boston Scientific’s first-generation WATCHMAN 2.5, and the same number of recipients of its successor WATCHMAN FLX. The rate of major in-hospital adverse events was 1.35% in the FLX arm and 2.4% in the Watchman 2.5 cohort.

Using information from a number of continuous data-stream sensors in implantable cardiac devices, Boston Scientific developed the HeartLogic Heart Failure Diagnostic, which can predict heart failure events on average 34 days before they happen. The algorithm alerts doctors of worsening conditions, allowing for earlier intervention and preventative action.

Boston Scientific has put forward real-world safety data gathered on its left atrial appendage occlusion device, the WATCHMAN FLX™. The latest data from Boston Scientific, which spanned more than 16,000 patients with atrial fibrillation not caused by heart valve problems who received the next-generation WATCHMAN FLX device, demonstrated favorable outcomes.

The COVID-19 pandemic has exacerbated the opioid epidemic, and the need for a broader menu of non-opioid treatment options has never been greater. Boston Scientific continues to invest in cutting-edge therapies to help patients and their doctors navigate the ever-changing pain management journey. The Boston Scientific WaveWriter Alpha™ Spinal Cord Stimulation System provides multiple therapy options that can be used in combination to help patients find relief.

Boston Scientific has spent approximately $1 billion buying stakes in about 50 companies globally through its ventures portfolio as a source for new innovation and potential mergers and acquisitions down the road. Since 2018, half of the 16 acquisitions the company completed went through Boston Scientific Ventures, including three of five acquisition targets in 2021.

Baptist Health cardiologist Salil Patel has performed the first procedure in Northeast Florida using the SYNERGY MEGATRON™ stent during a coronary procedure to eliminate blockages in a patient’s heart. The SYNERGY MEGATRON™ is designed for use in large proximal vessels and features architecture with increased strength as well as the ability to expand to 6.0mm in diameter and accommodate tapered vessels.

Mitchell Salloum became the first patient to receive a WATCHMAN™ implant in Wyoming. The Boston Scientific WATCHMAN implant is placed into a patient’s heart in a one-time procedure that may reduce stroke risk for a lifetime in patients with irregular heartbeats.

Many Fortune 500 companies have long-standing, well-oiled programs that often funnel into post-grad development and leadership programs or full-time jobs. For Lauren Nakamura, her marketing internship at Boston Scientific changed the course of her career and gave her confidence and reassurance that she was joining a workplace culture that prioritized work-life integration.

The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.

*The EMPOWER MPS is an investigational device and limited by U.S. law to investigational use only. It is not available for sale. Some device references are for informational purposes only and are pending CE Mark. Not available in the European Economic Area.

The global medical device manufacturer has maintained operational continuity throughout the pandemic, using clear processes and procedures mixed with a healthy dose of care.

Our innovative TheraSphere™ technology, which increases HCC liver cancer survival rates, may be an effective treatment for other tumors.

CIO and SVP of IT Jodi Euerle Eddy, recently named one of FiercePharma’s 2021 Fiercest Women in Life Sciences, reflects on her career and the opportunity to turn Boston Scientific’s digital transformation strategy into a competitive advantage.

Our CHAMPION AF clinical trial is studying whether the WATCHMAN FLX device can reduce the risk of stroke for more people suffering from AFib. Learn more about one patient enrolled in the trial in Sydney, Australia.

How Boston Scientific built a corporate culture of diversity and equity that encourages collaboration and innovation.

New high-resolution imaging solutions from Boston Scientific are designed to provide a clearer view of the human anatomy

In the race to secure computer chips amid a global shortage, medical device makers say they have found their ace card: their products save lives. Brad Sorenson, senior vice president, Global Supply Chain, shares how the company's' relationship with suppliers has helped Boston Scientific secure supply as typical lead times for components quintupled from three to 15 months.

Jodi Eddy, chief information and digital officer at Boston Scientific, explains the link between broadband access and telehealth access—and the subsequent impact on healthcare disparities.

Boston Scientific’s tumor-targeting glass microbeads continue to shatter expectations for cancer treatment. The latest results of a long-term study showed adding TheraSpheres to a standard chemotherapy regimen could extend survival for patients with colorectal cancer that has spread to the liver.

CAUTION: In the U.S., the use of TheraSphere for mCRC is for investigational use only as the safety and effectiveness have not been established.

As the University of Minnesota launches the Center for Medical Device Cybersecurity, KSTP reports how Boston Scientific is one of five Minnesota device companies that have provided funding.

Boston Scientific Chief Digital Health Officer David Feygin shares his career journey and leadership tips with professionals on the Ivy Podcast.

Boston Scientific recently announced FDA clearance of the EXALT Model B single-use bronchoscope, intended for bedside procedures in intensive care units or in the operating room. Medgadget had the opportunity to speak with Dave Pierce, Executive Vice President and President, MedSurg and President, Endoscopy, at Boston Scientific, about the new bronchoscope.

BostonScientific MedSurg EVP Dave Pierce shares his excitement for the future of our Endoscopy and Urology/Pelvic Health businesses, and why he’s proud of how the company has navigated through the uncertainty of the past year.

Boston Scientific has won FDA 510(k) clearance for a single-use bronchoscope designed to eliminate the infection risk associated with reusable devices.

Opinion: Boston Scientific's president of endoscopy writes that government policies have enabled the medtech giant to reinvest profits in multiple areas of innovation. "Patients cannot benefit from bets we don’t make.

A new study using Boston Scientific's EkoSonic endovascular system (EKOS) aims to address current gaps in clinical guidelines for the treatment of pulmonary embolism.

The advent of cardiac resynchronization therapy (CRT) changed the landscape of heart failure management options, but perhaps a third of patients receiving biventricular pacemakers for CRT don't respond to it. The observational study, SMART MSP, demonstrated that CRT with multisite LV pacing (MSP) made responders out of half of patients in whom CRT had failed over the previous 6 months in a prospective trial.

CMS granted a NTAP for single-use duodenoscopes, which applies to Boston Scientific's Exalt Model D single-use duodenoscope, as part of the FY 2022 hospital IPPS. This means that beginning Oct. 1, 2021, CMS will give hospitals additional device reimbursement when single-use duodenoscopes are used for eligible cases in the hospital inpatient setting.

David Knapp, Vice President of Research and Development for Peripheral Interventions at Boston Scientific, joins us to talk about the value of innovation culture, how businesses today go about creating and sustaining an innovative company and embracing the sustainability imperative.

Fueled by billions of its own dollars, the medical technology industry's successes are built on a willingness to invest with a long-term horizon. Some of our bets may never pay off, but our successes have the potential to transform millions of lives.

Boston Scientific has exerted its right to acquire the remaining shares of Farapulse, a company that has developed a pulsed field ablation system for the treatment of cardiac arrhythmias.

Vance Brown has worked in the company's legal department for 20 years. But he's facing new challenges as the GC, including the task of bringing a global workforce back to the office.